A combination of two highly effective drugs, pembrolizumab and axitinib, has demonstrated sustained efficacy in treating advanced kidney cancer. The conclusive results from the extensive KEYNOTE-426 study, recently published in Nature Medicine, confirm that this therapeutic approach significantly prolongs both overall survival and progression-free survival compared to standard sunitinib treatment. Patients in this groundbreaking study were followed for over five years, marking the longest follow-up period for similar clinical trials.
Pembrolizumab works by enhancing the body`s immune response to fight the tumor, while axitinib inhibits the growth of blood vessels that supply cancer cells. This combined regimen increased the median overall survival to 47.2 months, a notable improvement over the 40.8 months observed in the sunitinib group. Furthermore, the median progression-free survival was extended to 15.7 months, compared to 11.1 months with sunitinib. The overall response rate also showed superiority, with 60.6 percent for the combination versus 39.6 percent for sunitinib.
Researchers also investigated how various biomarkers, including genetic and protein characteristics of the tumor, influence treatment outcomes. Some markers, such as T-cell inflammatory activity or PD-L1 levels, may help in tailoring more precise therapies. However, further research is required to fully validate these findings and integrate them into clinical practice.
Despite the need for additional biomarker studies, the combination of pembrolizumab and axitinib is already considered a standard first-line therapy for advanced renal cell carcinoma. Experts emphasize that these treatment regimens have dramatically improved the prognosis for a disease previously known to be particularly challenging to treat.
In related research, scientists previously discovered that cancer can recur even after successful treatment due to external factors. Surprisingly, common viral infections were found to `awaken` dormant cancer cells in the lungs, potentially triggering the development of new metastases.
